How prepared are your patients for a severe hypoglycemic event?

A severe hypoglycemic episode can take place anytime, anywhere. Help your patients be ready with GlucaGen® HypoKit®.

It’s important for your patients to understand that untreated hypoglycemia may become severe and cause them to pass out. Prepare to treat them with GlucaGen® HypoKit®

GlucaGen® HypoKit® is a prescription glucagon emergency kit for the treatment of severe hypoglycemia.1 

Open GlucaGen HypoKit

GlucaGen® HypoKit® comes in a bright orange case designed to be noticeable.

It includes one vial of GlucaGen® (1 mg or 1 unit) and one disposable syringe with Sterile Water (1 mL) for Reconstitution.

GlucaGen® is contraindicated in patients with known hypersensitivity to glucagon, lactose, or any other constituent in GlucaGen® and in patients with known pheochromocytoma or insulinoma.

Consider prescribing two kits, so your patients have one GlucaGen® HypoKit® at work and one at home.

Prescription for GlucaGen HypoKit (2)

GlucaGen® is glucagon.


Download the Instructions for Use for GlucaGen® HypoKit®

Important Safety Information

Contraindications

  • GlucaGen® HypoKit® is contraindicated in patients with: 
    • Known hypersensitivity to glucagon, lactose or any other constituent in GlucaGen® HypoKit®
    • Pheochromocytoma
    • Insulinoma

Warnings and Precautions

  • Glucagon is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure, 5 to 10 mg of phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed
  • GlucaGen® HypoKit® should not be administered to patients suspected of having insulinoma
  • Caution should be observed in administering GlucaGen® HypoKit® to patients with glucagonoma
  • Allergic reactions may occur and include generalized rash, and in rare cases anaphylactic shock with breathing difficulties, and hypotension
  • In order for GlucaGen® HypoKit® treatment to reverse hypoglycemia, adequate amounts of glucose must be stored in the liver (as glycogen). Therefore, GlucaGen® HypoKit® should be used with caution in patients with conditions such as prolonged fasting, starvation, adrenal insufficiency or chronic hypoglycemia because these conditions result in low levels of releasable glucose in the liver and an inadequate reversal of hypoglycemia by GlucaGen® HypoKit® treatment.
  • Use with caution in patients with known cardiac disease, as glucagon increases myocardial oxygen demand
  • Blood glucose measurements may be considered to monitor the patient’s response

Adverse Reactions

  • Side effects may include nausea and vomiting at doses above 1 mg or with rapid injection
  • A temporary increase in both blood pressure and pulse rate may occur following administration

Drug Interactions

  • Beta-blockers: Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be temporary because of glucagon’s short half-life. The increase in blood pressure and pulse rate may require therapy in patients with pheochromocytoma or coronary artery disease 
  • Indomethacin: When used with indomethacin, glucagon may lose its ability to raise blood glucose or may even produce hypoglycemia 
  • Anticholinergics: Coadministration with an anticholinergic drug is not recommended due to increased gastrointestinal side effects 
  • Warfarin: Glucagon may increase the anticoagulant effect of warfarin
  • Insulin: Insulin reacts antagonistically towards glucagon. Therefore, caution should be exercised when glucagon is used as a diagnostic aid in patients with diabetes

GlucaGen® (glucagon [rDNA origin] for injection) HypoKit® Indications and Usage

GlucaGen® (glucagon [rDNA origin] for injection) HypoKit® is indicated to treat severe hypoglycemic reactions which may occur in patients with diabetes mellitus treated with insulin.    

Please click here for Prescribing Information. 

 

Reference

  1. GlucaGen [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2015.